semaglutide market Size, Share, Demand, Forecast, 2034 GLP-1 Weight Loss Drug Market

For aggressive diseases like cancer, trials typically avoid placebos, instead assigning one group an existing medicine while giving the other group the experimental drug

Furthermore, supplements are not FDA-regulated and may not be safe for everyone to take

This means the FDA is now (finally!) coming after the entire compounded GLP-1 market, including the injectable business that HIMS and others have been operating profitably for over a year since the semaglutide shortage was officially resolved in early 2025, largely without meaningful enforcement

The potential impact on their business specifically, and their sector more broadly, based on their product/service mix, customer profiles and geographic focus

The absolute NAION risk is small

Some patients report less nausea when injecting during eating windows, while others tolerate injection fine during fasts